Beenish Nafees
Research Subjects
Beenish Nafees has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
A Lloyd
United Biosource Corporation, London, UK
2 shared publicationsAj Lloyd
2 shared publicationsA.J. Lloyd
Oxford Outcomes, an ICON Plc Company, Oxford, UK
1 shared publicationC Kerr
1 shared publicationC. Deschaseaux
Novartis Pharma AG, Basel, Switzerland
1 shared publicationC. Patel
Icon PLC, Oxford, UK
1 shared publication
Latest Publications
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A448
Estimating Utilities / Disutilities for High Risk Metastatic Hormone-Sensitive Prostate Cancer (MHSPC) and Treatment-Related Adverse Events
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A448
Estimating Utilities / Disutilities for High Risk Metastatic Hormone-Sensitive Prostate Cancer (MHSPC) and Treatment-Related Adverse Events
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A637
A Societal Utility Study to Elicit Values for Adverse Events and Surgical Complications in Moderate to Severe Crohn’s Disease in UK
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A637
A Societal Utility Study to Elicit Values for Adverse Events and Surgical Complications in Moderate to Severe Crohn’s Disease in UK
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A493
Health State Utilities In Chronic Heart Failure In The Uk
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A493
Health State Utilities In Chronic Heart Failure In The Uk
- Top Cited PapersOpen Access
- 1 January 2008
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 84
Health state utilities for non small cell lung cancer
Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss.
- 1 January 2008
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 84
Top Cited PapersOpen AccessHealth state utilities for non small cell lung cancer
Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss.
- 31 December 2006
- Published by Elsevier in Value in Health
- Vol. 9 (6) , A296-A297
PCN69 HEALTH UTILITIES IN THE UK FOR SECOND LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PRIOR CHEMOTHERAPY
- 31 December 2006
- Published by Elsevier in Value in Health
- Vol. 9 (6) , A296-A297
PCN69 HEALTH UTILITIES IN THE UK FOR SECOND LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PRIOR CHEMOTHERAPY
- 1 October 2006
- Published by Taylor & Francis in European Diabetes Nursing
- Vol. 3 (2) , 92-97
How diabetes and insulin therapy affects the lives of people with type 1 diabetes
- 1 October 2006
- Published by Taylor & Francis in European Diabetes Nursing
- Vol. 3 (2) , 92-97
How diabetes and insulin therapy affects the lives of people with type 1 diabetes
- 31 December 2005
- Published by Elsevier in Value in Health
- Vol. 8 (6) , A48
PCN49 HEALTH STATE DESCRIPTIONS FOR METASTATIC BREAST CANCER: A QUALITATIVE STUDY
- 31 December 2005
- Published by Elsevier in Value in Health
- Vol. 8 (6) , A48
PCN49 HEALTH STATE DESCRIPTIONS FOR METASTATIC BREAST CANCER: A QUALITATIVE STUDY